SCHEMBL2369002

SCHEMBL2369002

Cc1cccc(CNc2nc(Cl)nc3scc(-c4ccc5c(c4)OCO5)c23)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.48
CYP1A2 P05177 7/20 0.44
CYP2D6 P10635 7/20 0.44
MAPK1 P28482 7/20 0.44
CLK4 Q9HAZ1 7/20 0.44
CYP3A4 P08684 6/20 0.44
LMNA P02545 4/20 0.44
TDP1 Q9NUW8 3/20 0.43
CLK1 P49759 3/20 0.43
CLK2 P49760 3/20 0.43
DYRK1A Q13627 3/20 0.43
DYRK1B Q9Y463 3/20 0.43
CLK3 P49761 1/20 0.43
PIP4K2C Q8TBX8 1/20 0.43
CYP2C19 P33261 6/20 0.42
TSHR P16473 6/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HSD17B10 Q99714 4/20 0.42
KDM4E B2RXH2 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369182 0.86 CLK4 (0.52) ESR1CYP1A2CYP2D6MAPK1CLK4
SCHEMBL2368333 0.86 TSHR (0.43) ESR1CYP1A2CYP2D6MAPK1CLK4
SCHEMBL6357825 0.86 CYP1A2 (0.44) CYP1A2CYP2D6MAPK1CLK4CYP3A4
SCHEMBL2368958 0.85 CYP1A2 (0.41) ESR1CYP1A2CYP2D6MAPK1CLK4
SCHEMBL2369291 0.85 CYP1A2 (0.41) ESR1CYP1A2CYP2D6MAPK1CLK4
SCHEMBL2368351 0.84 CCNE2 (0.41) ESR1CYP1A2CYP2D6MAPK1CLK4
SCHEMBL2368616 0.83 MEN1 (0.42) CYP1A2CYP2D6MAPK1CLK4CYP3A4
SCHEMBL2368773 0.83 ESR1 (0.70) ESR1MAPK1LMNAPIP4K2CMAPT
SCHEMBL2369261 0.82 SMN1; SMN2 (0.43) CYP1A2CYP2D6MAPK1CLK4CYP3A4
SCHEMBL3383460 0.82 PRKCZ (0.43) CYP1A2CYP2D6MAPK1CLK4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 ESR1 4494/4885CYP1A2 226/4885CYP2D6 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.